UroGen Pharma Ltd. (URGN) - Q2 2026 Filing Summary
Business Context and Reporting Period
This summary covers the unaudited quarterly report (Form 10-Q) for UroGen Pharma Ltd. for the period ended June 30, 2026. UroGen is a biotechnology company focused on urothelial and specialty cancers, utilizing its proprietary RTGel technology. The company currently commercializes two FDA-approved products: Jelmyto (for low-grade upper tract urothelial cancer) and Zusduri (for recurrent low-grade intermediate risk non-muscle invasive bladder cancer, approved June 2025). The company operates as a single segment and is incorporated in Israel with principal executive offices in Princeton, New Jersey.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $72.5 million | $24.2 million | $123.4 million | $44.5 million |
| Gross Profit | $65.9 million | $20.7 million | $112.7 million | $38.6 million |
| Gross Margin | 91% | 85% | 91% | 87% |
| Net Loss | $(14.4) million | $(49.9) million | $(37.9) million | $(93.8) million |
| Operating Loss | $(0.1) million | $(41.4) million | $(20.2) million | $(78.4) million |
| Cash & Equivalents | $79.1 million (as of June 30, 2026) | |||
| Marketable Securities | ||||
| Total Liquidity | $108.0 million | |||
| Long-Term Debt | $188.7 million (Carrying Value) | |||
| Prepaid Forward Obligation | $125.1 million (Carrying Value) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 200% year-over-year for the quarter and 178% year-over-year for the six months. This growth is primarily driven by the commercial launch of Zusduri in late June 2025, which generated $50.4 million in Q2 2026 revenue compared to zero in the prior year.
- Profitability Improvement: The company significantly reduced its net loss, narrowing from $49.9 million in Q2 2025 to $14.4 million in Q2 2026. Operating loss improved from $41.4 million to a near-breakeven $0.1 million due to revenue scaling outpacing expense growth.
- Debt Refinancing: In February 2026, the company entered a new loan agreement with Pharmakon, refinancing existing debt and drawing a new tranche. This increased the carrying value of long-term debt from $122.2 million (Dec 2025) to $188.7 million (June 2026).
- Accounts Receivable: Accounts receivable increased significantly to $88.8 million from $33.1 million at year-end 2025, reflecting the ramp-up in sales volume for Zusduri.
Guidance, Outlook, and Management Commentary
- Commercialization: Management highlights the successful adoption of Zusduri, noting it is the first and only FDA-approved non-surgical treatment for its indication. The company has expanded its sales force and commercial infrastructure to support both products.
- Pipeline Progress:
- UGN-103: Phase 3 UTOPIA trial enrollment is complete. The company plans to submit an NDA in Q3 2026, with potential FDA approval in 2027.
- UGN-104: Phase 3 trial initiated in June 2025; enrollment expected to complete by end of 2026.
- UGN-501: FDA cleared the IND for this oncolytic virus therapy in July 2026; Phase 1 trial expected to begin in Q4 2026.
- UGN-301: Development discontinued in November 2025; license with Agenus terminated.
- Liquidity: Management believes current cash, cash equivalents, and marketable securities ($108.0 million) are sufficient to fund operations beyond one year from the filing date. However, the company may need to raise additional capital in the future if product sales do not generate sufficient cash flow.
- Legal Settlement: In June 2026, the company settled patent litigation with Teva Pharmaceuticals regarding Jelmyto. Teva received a non-exclusive license to sell a generic version beginning September 15, 2030, subject to FDA approval.
Investor Verification Checklist
- Debt Covenants: Verify the specific financial covenants and restrictions in the new 2026 Pharmakon Loan Agreement, particularly regarding additional indebtedness and dividend payments.
- RTW Obligation: Review the tiered payment structure of the Prepaid Forward Obligation with RTW Investments, as payments are based on a percentage of net sales and impact future cash flows.
- Supply Chain: Confirm the status of the April 2026 supply agreement with TAPI NL B.V. for mitomycin, the sole source for the active ingredient in Jelmyto and Zusduri.
- Reimbursement: Monitor the status of the New Technology Ambulatory Payment Classification (APC) for Jelmyto and the permanent J-code for Zusduri to ensure continued Medicare coverage.
- Patent Expiry: Note that orphan drug exclusivity for Jelmyto expires in April 2027, though the settlement with Teva delays generic entry until 2030.